Alpha-1 antitrypsin therapy is safe and well tolerated in children and adolescents with recent onset type 1 diabetes mellitus

Pediatric Diabetes

Volumn 17, Issue 5, 2016, Pages 351-359

  Rachmiel, Marianna ^a,b   Strauss, Pnina ^c   Dror, Nitzan ^d   Benzaquen, Hadassa ^d   Horesh, Orit ^d   Tov, Nave ^c   Weintrob, Naomi ^b,e   Landau, Zohar ^b,f   Ben Ami, Michal ^g   Haim, Alon ^h,i   Phillip, Moshe ^b,d   Bistritzer, Tzvi ^a,b   Lewis, Eli C ⁱ   Lebenthal, Yael ^b,d  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Kamada Ltd   (Israel)

^d SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^e TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^f WOLFSON MEDICAL CENTER   (Israel)

^g SHEBA MEDICAL CENTER   (Israel)

^h BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

ⁱ BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

adverse events; alpha 1 antitrypsin; beta cell preservation; children; phase I II trial; recent onset diabetes

Indexed keywords

ALPHA 1 ANTITRYPSIN; AUTOANTIBODY; C PEPTIDE; HEMOGLOBIN A1C; INSULIN; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; ADOLESCENT DISEASE; AREA UNDER THE CURVE; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA EROSION; COUGHING; DIABETIC KETOACIDOSIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG INFORMATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; FEVER; GLYCEMIC CONTROL; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HUNGER; HYPOGLYCEMIA; HYPOTENSION; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MALE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; OROPHARYNX PAIN; OTALGIA; PANCREAS ISLET BETA CELL; PEDIATRICS; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHYSICAL DISABILITY; PHYSICAL EXAMINATION; PREPUBERTY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SEXUAL MATURATION; SIDE EFFECT; TREATMENT DURATION; VERTIGO;

EID: 84977510956     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12283     Document Type: Article

References (32)

1. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986: 314: 1360–1368.
2. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003: 26: 832–836.
3. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care 2015: 38 (Suppl. 1): S8–S16.
4. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 2010: 160: 176–184.
5. Breit SN, Wakefield D, Robinson JP, Luckhurst E, Clark P, Penny R. The role of alpha 1-antitrypsin deficiency in the pathogenesis of immune disorders. Clin Immunol Immunopathol 1985: 35: 363–380.
6. Lou J, Triponez F, Oberholzer J et al. Expression of alpha-1 proteinase inhibitor in human islet microvascular endothelial cells. Diabetes 1999: 48: 1773–1778.
7. American Thoracic Society/European Respiratory Society statement. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003: 168: 818–900.
8. Ganrot PO, Gydell K, Ekelund H. Serum concentration of alpha-2-macroglobulin, haptoglobin and alpha-1-antitrypsin in diabetes mellitus. Acta Endocrinol (Copenh) 1967: 55: 537–544.
9. Hashemi M, Naderi M, Rashidi H, Ghavami S. Impaired activity of serum alpha-1-antitrypsin in diabetes mellitus. Diabetes Res Clin Pract 2007: 75: 246–248.
10. Lisowska-Myjak B, Pachecka J, Kaczynska B, Miszkurka G, Kadziela K. Serum protease inhibitor concentrations and total antitrypsin activity in diabetic and non-diabetic children during adolescence. Acta Diabetol 2006: 43: 88–92.
11. Sandler M, Gemperli BM, Hanekom C, Kuhn SH. Serum alpha 1-protease inhibitor in diabetes mellitus: reduced concentration and impaired activity. Diabetes Res Clin Pract 1988: 5: 249–255.
12. Lewis EC, Mizrahi M, Toledano M et al. alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci U S A 2008: 105: 16236–16241.
13. Ma H, Lu Y, Li H et al. Intradermal alpha1-antitrypsin therapy avoids fatal anaphylaxis, prevents type 1 diabetes and reverses hyperglycaemia in the NOD mouse model of the disease. Diabetologia 2010: 53: 2198–2204.
14. Koulmanda M, Bhasin M, Hoffman L et al. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A 2008: 105: 16242–16247.
15. Gottlieb PA, Alkanani AK, Michels AW et al. α1−Antitrypsin therapy downregulates toll-like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes. J Clin Endocrinol Metab 2014: 99: E1418–E1426.
16. Rewers MJ, Pillay K, de Beaufort C et al. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 2014: 15 (Suppl. 20): 102–114.
17. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM et al. CDC growth charts: United States. Adv Data 2000: 314: 1–27.
18. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969: 44: 291–303.
19. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970: 45: 13–23.
20. Greenbaum CJ, Harrison LC. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 2003: 52: 1059–1065.
21. Greenbaum CJ, Beam CA, Boulware D et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes 2012: 61: 2066–2073.
22. Herold KC, Gitelman SE, Masharani U et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005: 54: 1763–1769.
23. Abecassis A, Schuster R, Shahaf G et al. α1-antitrypsin increases interleukin-1 receptor antagonist production during pancreatic islet graft transplantation. Cell Mol Immunol 2014: 11: 377–386.
24. Bellacen K, Kalay N, Ozeri E, Shahaf G, Lewis EC. Revascularization of pancreatic islet allografts is enhanced by α-1-antitrypsin under anti-inflammatory conditions. Cell Transplant 2013: 22: 2119–2133.
25. Shahaf G, Moser H, Ozeri E, Mizrahi M, Abecassis A, Lewis EC. α-1-antitrypsin gene delivery reduces inflammation, increases T-regulatory cell population size and prevents islet allograft rejection. Mol Med 2011: 17: 1000–1011.
26. Cemeroglu AP, Thomas JP, Zande LT et al. Basal and bolus insulin requirements in children, adolescents, and young adults with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (CSII): effects of age and puberty. Endocr Pract 2013: 19: 805–811.
27. Szadkowska A, Pietrzak I, Mianowska B et al. Insulin sensitivity in type 1 diabetic children and adolescents. Diabet Med 2008: 25: 282–288.
28. Gabbay MA, Sato MN, Finazzo C, Duarte AJ, Dib SA. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus. Arch Pediatr Adolesc Med 2012: 166: 601–607.
29. Wherrett DK, Bundy B, Becker DJ et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011: 378: 319–327.
30. Lazar L, Ofan R, Weintrob N et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 2007: 23: 286–291.
31. Orban T, Bundy B, Becker DJ et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011: 378: 412–419.
32. Sherry N, Hagopian W, Ludvigsson J et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011: 378: 487–497.